JP2025516501A5 - - Google Patents
Info
- Publication number
- JP2025516501A5 JP2025516501A5 JP2024564822A JP2024564822A JP2025516501A5 JP 2025516501 A5 JP2025516501 A5 JP 2025516501A5 JP 2024564822 A JP2024564822 A JP 2024564822A JP 2024564822 A JP2024564822 A JP 2024564822A JP 2025516501 A5 JP2025516501 A5 JP 2025516501A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- section
- composition according
- irak4
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340692P | 2022-05-11 | 2022-05-11 | |
| US63/340,692 | 2022-05-11 | ||
| PCT/US2023/021812 WO2023220227A1 (en) | 2022-05-11 | 2023-05-11 | Treating diseases and disorders with irak4-modifying compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516501A JP2025516501A (ja) | 2025-05-30 |
| JP2025516501A5 true JP2025516501A5 (enExample) | 2026-05-19 |
Family
ID=88730953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564822A Pending JP2025516501A (ja) | 2022-05-11 | 2023-05-11 | Ｉｒａｋ４修飾化合物による疾患及び障害の治療 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4522772A4 (enExample) |
| JP (1) | JP2025516501A (enExample) |
| KR (1) | KR20250011914A (enExample) |
| CN (1) | CN119156458A (enExample) |
| AU (1) | AU2023269214A1 (enExample) |
| CA (1) | CA3251930A1 (enExample) |
| IL (1) | IL316793A (enExample) |
| MX (1) | MX2024013649A (enExample) |
| WO (1) | WO2023220227A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| US12178821B2 (en) | 2021-04-08 | 2024-12-31 | Curis, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818419B2 (en) * | 2000-01-13 | 2004-11-16 | Tularik Inc. | IRAK-4: compositions and methods of use |
| WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| CN108024971A (zh) * | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| CN120267671A (zh) * | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| MX2020003666A (es) * | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
| KR20230048358A (ko) * | 2020-08-03 | 2023-04-11 | 쿠리스 인코퍼레이션 | 질환 및 장애를 치료하기 위한 조성물 및 방법 |
| WO2022108996A1 (en) * | 2020-11-18 | 2022-05-27 | Curis, Inc. | Methods of treating diseases and disorders |
-
2023
- 2023-05-11 IL IL316793A patent/IL316793A/en unknown
- 2023-05-11 JP JP2024564822A patent/JP2025516501A/ja active Pending
- 2023-05-11 CN CN202380038247.XA patent/CN119156458A/zh active Pending
- 2023-05-11 AU AU2023269214A patent/AU2023269214A1/en active Pending
- 2023-05-11 CA CA3251930A patent/CA3251930A1/en active Pending
- 2023-05-11 KR KR1020247040259A patent/KR20250011914A/ko active Pending
- 2023-05-11 EP EP23804237.8A patent/EP4522772A4/en active Pending
- 2023-05-11 WO PCT/US2023/021812 patent/WO2023220227A1/en not_active Ceased
- 2023-05-11 MX MX2024013649A patent/MX2024013649A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550739A5 (enExample) | ||
| CN107873032B (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
| ES3054136T3 (en) | Irak degraders and uses thereof | |
| RU2453548C2 (ru) | Азаиндолы, полезные в качестве ингибиторов янус-киназ | |
| US10150780B2 (en) | Spirocyclic heterocycle compounds useful as HIV integrase inhibitors | |
| CN114732910B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| CN107995911B (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
| US20190152970A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
| JP2023537477A5 (enExample) | ||
| ES2811834T3 (es) | Formas cristalinas de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida | |
| CN102711766A (zh) | N-9-取代的嘌呤化合物、组合物和使用方法 | |
| CN116710776A (zh) | 治疗疾病和病症的方法 | |
| EP4522772A1 (en) | Treating diseases and disorders with irak4-modifying compounds | |
| HK40042521B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| HK40042000B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| HK40096682A (zh) | 治疗疾病和病症的方法 | |
| HK40042000A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| HK40039385B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| HK40039385A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| HK1254517B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| HK1253003B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| CN104788365A (zh) | 异烟酰胺衍生物、其制备方法及应用 |